Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03225612Not ApplicableUnknown

Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)

Role: lead

NCT02574650Not ApplicableUnknown

Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.

Role: lead

NCT01740583Not ApplicableUnknown

Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation

Role: lead

NCT01852149Not ApplicableCompleted

Mitralign Percutaneous Annuloplasty First in Man Study

Role: lead

All 4 trials loaded